Double hit strategy using pH-sensitive liposomes containing doxorubicin and pheophorbide-a for combination tumor therapy
Source abstract
Abstract
For successful combination therapy using nanoparticles, stable loading and targeted delivery of different drugs are important. Herein, we prepared pH-sensitive liposomes with hydrophilic doxorubicin (Dox) in the core and hydrophobic pheophobide-a (Pba) in the lipid membrane (pH-lipo-Dox-Pba). The liposomes provided high drug accumulation in tumor tissue, with an enhanced permeability and retention (EPR) effect and enhanced binding to tumor cells by cyclic Arg-Gly-Asp peptide (cRGD). After cellular uptake, Dox was released in response to the endo-lysosomal acidic pH and moved into the nucleus, while Pba remained in the cytosol. Therefore, a double hit strategy composed of a simultaneous attack on nucleus and cytosol could be achieved by chemo- and photodynamic therapy. High tumor accumulation of pH-lipo-Dox-Pba was observed after intravenous injection into 4T1 tumor-bearing mice. Effective suppression of tumor growth in the same mouse model demonstrated a synergetic effect of combination therapy enabled by the double hit strategy using pH-lipo-Dox-Pba.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Kolesar · Am. J. Health Syst. Pharm. · 2021 · 78 · 99910.1093/ajhp/zxab084 ↗
2. Dusetzina · JAMA · 2021 · 325 · 52710.1001/jama.2020.25424 ↗
3. Vargason · Nat. Biomed. Eng. · 2021 · 5 · 95110.1038/s41551-021-00698-w ↗
4. Koo · Acc. Chem. Res. · 2011 · 44 · 101810.1021/ar2000138 ↗
5. Maeda · J. Control. Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
6. Greco · Adv. Drug Deliv. Rev. · 2009 · 61 · 120310.1016/j.addr.2009.05.006 ↗
7. Rawal · J. Control. Release · 2019 · 301 · 7610.1016/j.jconrel.2019.03.015 ↗
8. Barenholz · J. Control. Release · 2012 · 160 · 11710.1016/j.jconrel.2012.03.020 ↗
9. Liang · Adv. Mater. · 2018 · 30 · 170696310.1002/adma.201706963 ↗
10. Lee · Bioactive Mater. · 2022 · 8 · 2010.1016/j.bioactmat.2021.06.019 ↗
11. Ma · Pharm. Res. · 2018 · 35 · 5710.1007/s11095-017-2295-z ↗
12. Cui · Adv. Mater. Interfaces · 2020 · 7 · 200029210.1002/admi.202000292 ↗
13. Lovell · Chem. Rev. · 2010 · 110 · 283910.1021/cr900236h ↗
14. Rehman · Eur. J. Pharm. Biopharm. · 2018 · 133 · 33110.1016/j.ejpb.2018.11.001 ↗
15. Choi · Int. J. Pharm. · 2017 · 532 · 67710.1016/j.ijpharm.2017.03.007 ↗
16. Lee · Exp. Therapeut. Med. · 2018 · 15 · 4950
17. Bergstrand · Biophys. Chem. · 2003 · 104 · 36110.1016/S0301-4622(03)00011-5 ↗
18. Wang · Nanomed. Nanotechnol. Biol. Med. · 2012 · 8 · 19410.1016/j.nano.2011.06.006 ↗
19. Lu · Nanoscale · 2018 · 10 · 995710.1039/C8NR01184B ↗
20. Fleischmann · ACS Appl. Mater. Interfaces · 2020 · 12 · 3468910.1021/acsami.0c10057 ↗
21. Wu · Angew. Chem. Int. Ed. · 2021 · 60 · 1110410.1002/anie.202014162 ↗
22. Lee · ACS Appl. Mater. Interfaces · 2021 · 13 · 1081210.1021/acsami.1c02316 ↗
23. Jain · J. Nanopart. Res. · 2013 · 15
24. De Beer · Eur. J. Pharmacol. · 2001 · 415 · 110.1016/S0014-2999(01)00765-8 ↗
25. Horwitz · Ann. Oncol. · 1994 · 5 · S3
26. Park · J. Control. Release · 2006 · 115 · 3710.1016/j.jconrel.2006.07.011 ↗
27. Manickam · Bioconjug. Chem. · 2006 · 17 · 139510.1021/bc060104k ↗
28. Peng · Acta Biomater. · 2020 · 105 · 22310.1016/j.actbio.2020.01.005 ↗
29. Son · Adv. Drug Deliv. Rev. · 2019 · 138 · 13310.1016/j.addr.2018.10.002 ↗